Integrative Oncology Outcomes Study in Breast Cancer (IO-OS-BC)
This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrated Oncology (IO) and their effects on breast cancer patients in community settings.
Hypothesis: IO services improve patients' quality of life and decrease cancer recurrence rates in breast cancer patients as compared to women with similar disease states and prognoses who do not receive IO care, and may or may not use CAM treatment on their own.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study|
- Aim 1: Describe treatments received by breast cancer patients receiving physician level practitioner IO care and the cost of IO care. [ Time Frame: Baseline, 6, 12, 24, 36, 48, and 60 months post study enrollment. ] [ Designated as safety issue: No ]Will also describe how long after diagnosis women with breast cancer seek IO care and differences in IO care prescriptions associated with when, in a woman's course of treatment, she seeks care. This patient cohort will consist of all female patients with breast cancer seeking IO clinic care. Our analyses will describe how long after diagnosis women with breast cancer seek IO care and describe differences in IO care prescriptions associated with when, in a woman's course of treatment, she seeks care.
- Aim 2: Compare health-related quality of life (HRQOL) experienced by a group of breast cancer patients receiving IO care with HRQOL of a group of matched comparison women. [ Time Frame: 6-60 months post-enrollment ] [ Designated as safety issue: No ]Comparison will be between breast cancer patients living in the same geographic area with similar prognostic characteristics (age, stage of cancer at diagnosis, estrogen receptor/ progesterone receptor (ER/PR) status, race, ethnicity, and marital status) at the time of their initial diagnosis with breast cancer who did not receive IO care. We will identify an average of three (up to four each) matched controls for each eligible IO clinic cancer patient from the Western Washington CSS database and to invite them to enroll in the outcomes study.
- Aim 3: Collect pilot data on survival, comorbidities, and abnormal laboratory values. [ Time Frame: 6-60 months post-enrollment ] [ Designated as safety issue: No ]Collect pilot data on disease-free, progression free, and overall survival, as well as comorbidities and abnormal laboratory values at 6 months post-enrollment for all Cohort 1 and Cohort 2. We will collect data at 1 year post-enrollment and then yearly on disease-free, progression free, and overall survival, as well as comorbidities for as long as funding is available in a nested cohort of IO breast cancer patients (Cohort 1A) and their matched comparison group who did not receive care at any of the IO clinical sites (Cohort 2).
- Aim 4: Describe and compare CAM treatments [ Time Frame: Baseline, 6, 12, 24, 48, and 60 months ] [ Designated as safety issue: No ]Describe and compare the frequency of use of a variety of CAM treatments used by breast cancer patients who do (Cohort 1A) and do not (Cohorts 2A and 2B) receive IO care from an IO specialist.
- Aim 5: Compare the HRQOL of women who self-prescribe CAM with those who do not [ Time Frame: Baseline and 6, 12, 24, 36, 48 and 60 months post-enrollment ] [ Designated as safety issue: No ]To compare baseline and changes in HRQOL in breast cancer patients who self-prescribe CAM (Cohort 2B) matched with comparison women who do not use CAM (Cohort 2A).
|Study Start Date:||August 2010|
|Estimated Study Completion Date:||April 2015|
|Estimated Primary Completion Date:||April 2015 (Final data collection date for primary outcome measure)|
IO Clinic Breast Cancer Patients
Includes patients who are receiving care for their breast cancer at participating Seattle area IO clinics.
CSS Match-Control Patients
For each IO clinic patient, an average of two (up to four) matched comparison cases will be recruited from the Washington State Cancer Surveillance System (CSS). Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.
|Contact: Leanna J. Standish, ND, PhD, FABNOemail@example.com|
|Contact: M. Robyn Andersen, PhD, MPHfirstname.lastname@example.org|
|United States, Washington|
|Red Cedar Wellness Center||Recruiting|
|Bellevue, Washington, United States, 98004|
|Contact: RCWC Reception 425-451-0999 email@example.com|
|Principal Investigator: Janelle Martin, ND, FABNO|
|Principal Investigator: Laura A James, ND, FABNO|
|Bastyr Integrative Oncology Research Center||Recruiting|
|Kenmore, Washington, United States, 98028|
|Contact: Leanna J. Standish, ND, PhD, LAc, FABNO 425-602-3166 firstname.lastname@example.org|
|Principal Investigator: Leanna J. Standish, ND PhD FABNO|
|Seattle Integrative Oncology at Providence Integrative Cancer Care||Recruiting|
|Lacey, Washington, United States, 98503|
|Contact: Chad Aschtgen, ND, FABNO 360-412-8951 email@example.com|
|Principal Investigator: Chad Aschtgen, ND, FABNO|
|Seattle Cancer Treatment & Wellness Center||Recruiting|
|Renton, Washington, United States, 98057|
|Contact: Paul Reilly, ND, LAc, FABNO 425-204-7480 firstname.lastname@example.org|
|Principal Investigator: Paul Reilly, ND, FABNO|
|Sub-Investigator: Mark Gignac, ND, FABNO|
|Sub-Investigator: Erin Sweet, ND, FABNO|
|Seattle Integrative Oncology at Institute of Complementary Medicine||Recruiting|
|Seattle, Washington, United States, 98122|
|Contact: Chad Aschtgen, ND, FABNO 206-726-0034 email@example.com|
|Principal Investigator: Chad Aschtgen, ND, FABNO|
|Principal Investigator:||Leanna J. Standish, ND, PhD, FABNO||Bastyr University|
|Principal Investigator:||M. Robyn Andersen, PhD, MPH||Fred Hutchinson Cancer Research Center|